<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743791</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20020131</org_study_id>
    <nct_id>NCT04743791</nct_id>
  </id_info>
  <brief_title>Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma</brief_title>
  <official_title>A Randomized, Placebo-controlled, Parallel Group Study Designed to Assess the Change in Mucociliary Clearance After 12 Weeks of Treatment With Dupilumab in Patients With Moderate to Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sally E. Wenzel MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, placebo- controlled study to assess change in mucociliary&#xD;
      clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Dupilumab and placebo will be provided in identically matched 1.14 mL pre-filled syringes. To protect the blind, each treatment kit of 1.14 mL (dupilumab / placebo) glass pre-filled syringes will be prepared such that the treatments (dupilumab and its matching placebo) are identical and indistinguishable and will be labeled with a treatment kit number. The randomized treatment kit number list will be generated by Sanofi Regeneron</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mucociliary clearance (MCC) rate</measure>
    <time_frame>Measured at 12 weeks after the start of treatment</time_frame>
    <description>MCC is measured using an aerosol-based nuclear imaging technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1% predicted</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Assessed using spirometry after bronchodilator administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACT score</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Measured via the Asthma Control Test questionnaire. Scores range from 5 (poor control of asthma) to 25 (complete control of asthma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sputum eosinophils and T2 gene mean</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Measured via sputum induction to obtain airway cells and fluid from patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mucus plugging score by CT</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Radiologists will visually assess the presence or absence of mucus plugging in segmental airways and will provide a mucus plugging score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole lung MCC90, AAC90</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Measured via mucociliary clearance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral and central lung MCC90, MCC240, AAC90</measure>
    <time_frame>Measured from baseline to 12 weeks after start of treatment</time_frame>
    <description>Measured via mucociliary clearance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sucrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in&#xD;
             one second (FEV1) &lt;90% predicted, on medium to high dose inhaled corticosteroids (ICS)&#xD;
             with or without a second controller&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)&#xD;
&#xD;
          -  Reversibility &gt;/= 12% at screening or within the past 2 years, or a positive&#xD;
             methacholine challenge test within the past 2 years, or a positive methacholine&#xD;
             challenge during screening&#xD;
&#xD;
          -  FEV1/Forced Vital Capacity (FVC)&lt;75%&#xD;
&#xD;
          -  Blood Eosinophils (EOS) &gt;300 cells per mm3&#xD;
&#xD;
          -  Exhaled Nitric Oxide (FeNO) &gt;25 parts per billion (ppb)&#xD;
&#xD;
          -  Asthma Control Test (ACT) score &lt;20&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, nursing, or unwilling to test for pregnancy&#xD;
&#xD;
          -  Current smoker or &gt;10 pack year smoking history&#xD;
&#xD;
          -  Body Mass Index (BMI)&gt;37&#xD;
&#xD;
          -  Respiratory infection in the last 30 days&#xD;
&#xD;
          -  Use of antibiotics or oral prednisone in the last 30 days&#xD;
&#xD;
          -  Current or previous use of dupilumab&#xD;
&#xD;
          -  Current or recent use of anti-IL-5 therapies&#xD;
&#xD;
          -  Any other criteria that place the subject at unnecessary risk&#xD;
&#xD;
          -  Diagnosis of other lung diseases including Chronic Obstructive Pulmonary Disease&#xD;
             (COPD)&#xD;
&#xD;
          -  History of non-skin cell cancer in the last 5 years&#xD;
&#xD;
          -  Drug or alcohol addiction in the last 5 years&#xD;
&#xD;
          -  Any other uncontrolled disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa Ilnicki, RRT RPSGT</last_name>
    <phone>412-864-0865</phone>
    <email>ilnickima@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Pittsburgh Asthma Institute at UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sally Wenzel, MD</last_name>
      <phone>412-647-9955</phone>
      <email>swenzel@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Ilnicki, RRT RPSGT</last_name>
      <phone>412-864-0865</phone>
      <email>ilnickima@upmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sally E. Wenzel MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

